Calithera Biosciences (CALA) Reports Q3 Loss of $0.49/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Calithera Biosciences Reports Third Quarter 2015 Financial Results and Recent Highlights
November 9, 2015 4:05 PM EST-Single Agent Solid Tumor Clinical Benefit Seen With Tumor Metabolism Inhibitor CB-839
-Continued Signs of Activity, Tolerability, and Durability
-First Preclinical Data Presented For Immuno-Oncology Arginase Inhibitor CB-1158
-IND filing Remains on Track for 1H 2016
-Calithera to Host Conference Call Today at 4:15pm Eastern Time
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage... More
